Perspective Therapeutics (CATX) Receivables (2011 - 2026)

Perspective Therapeutics has disclosed Receivables across 16 years of filings, most recently posting $58000.0 for Q1 2026.

• Receivables for Q1 2026 came in at $58000.0, down 25.64% year-over-year; the trailing twelve-month figure through Mar 2026 was $58000.0 (down 25.64% YoY), and the FY2025 annual result was $16000.0, down 97.35% from the prior year.
• Receivables came in at $58000.0 for Q1 2026 at Perspective Therapeutics, up from $16000.0 in the prior quarter.
• In the past five years, Receivables ranged from a high of $2.1 million in Q1 2022 to a low of $16000.0 in Q4 2025.
• The 5-year median for Receivables is $999000.0 (2024), against an average of $837823.5.
• Peak annual rise in Receivables reached 58.45% in 2025, while the deepest fall reached 97.35% in 2025.
• Perspective Therapeutics' Receivables stood at $1.4 million in 2022, then dropped by 13.92% to $1.2 million in 2023, then plunged by 48.68% to $603000.0 in 2024, then slumped by 97.35% to $16000.0 in 2025, then jumped by 262.5% to $58000.0 in 2026.
• The last three Receivables figures came in at $58000.0 (Q1 2026), $16000.0 (Q4 2025), and $179000.0 (Q3 2025), per Business Quant data.